World's Best Scientists 2026 revealed!
Michele Milella

Michele Milella

D-Index & Metrics

Medicine

D-Index
76
Citations
30406
World Ranking
18640
National Ranking
753

Overview

Michele Milella is affiliated with the University of Verona in Italy and has a significant body of research primarily within the field of Medicine. Their research focuses extensively on Oncology, Pulmonary and Respiratory Medicine, and Cancer Research, with additional work in Molecular Biology and Surgery. This body of work covers numerous specialized topics including Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, and Cancer Immunotherapy and Biomarkers.

They have contributed to multiple high-impact journals, frequently publishing in the following venues:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancers
  • Frontiers in Oncology
  • ESMO Open

Their research collaborations include repeated partnerships with a number of co-authors:

  • Sara Pilotto
  • Alice Avancini
  • Ilaria Trestini
  • Lorenzo Belluomini
  • Daniela Tregnago

Examples of recent published articles include:

  • "Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial" (2020, Journal for ImmunoTherapy of Cancer)
  • "Molecular Tumor Boards in Clinical Practice" (2020, Trends in Cancer)
  • "Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study" (2023, The Lancet Oncology)
  • "Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size" (2021, Gut)
  • "Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions" (2021, Cancers)

Their published research addresses key topics such as treatment trials for metastatic cancers, molecular diagnostics in oncology, and biomarker development to predict immunotherapy responses. The work spans clinical trials, molecular tumor board strategies, and genetic characteristics of various cancer types.

In terms of academic output, Michele Milella's contributions have accumulated citations reflecting engagement within the cancer research community, with some papers reaching well over a hundred citations, indicating a sustained influence relevant to clinical oncology and cancer biology.

Best Publications

  • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

    Rafael Rosell;Enric Carcereny;Radj Gervais;Alain Vergnenegre

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • ROLES OF THE RAF/MEK/ERK PATHWAY IN CELL GROWTH, MALIGNANT TRANSFORMATION AND DRUG RESISTANCE

    James A. McCubrey;Linda S. Steelman;William H. Chappell;Stephen L. Abrams

  • Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

    Howard L. Kaufman;Jeffery Russell;Omid Hamid;Shailender Bhatia

  • Patterns of somatic structural variation in human cancer genomes

    Yilong Li;Nicola D Roberts;Jeremiah A Wala;Jeremiah A Wala;Ofer Shapira;Ofer Shapira

  • Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

    Linda S. Steelman;William H. Chappell;Stephen L. Abrams;C. Ruth Kempf

  • Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

    William H. Chappell;Linda S. Steelman;Jacquelyn M. Long;Ruth C. Kempf

  • PTEN: Multiple Functions in Human Malignant Tumors

    Michele Milella;Italia Falcone;Fabiana Conciatori;Ursula Cesta Incani

  • Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia

    L. S. Steelman;S. L. Abrams;J. Whelan;F. E. Bertrand

  • Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia

    Michele Milella;Steven M. Kornblau;Zeev Estrov;Bing Z. Carter

  • Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.

    Donatella Del Bufalo;Ludovica Ciuffreda;Daniela Trisciuoglio;Marianna Desideri

  • Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

    Luisa Carbognin;Sara Pilotto;Michele Milella;Vanja Vaccaro

  • Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mtor cascades which alter therapy response

    James A McCubrey;Linda S Steelman;William H Chappell;Stephen L Abrams

  • FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

    Vaccaro;Sperduti I;Milella M

  • Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

    James Andrew McCubrey;Linda S. Steelman;William H. Chappell;Stephen L. Abrams

  • Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial.

    Howard L. Kaufman;Jeffery S. Russell;Omid Hamid;Shailender Bhatia

  • Cytokine-regulated expression of survivin in myeloid leukemia.

    Bing Z. Carter;Michele Milella;Michele Milella;Dario C. Altieri;Dario C. Altieri;Michael Andreeff;Michael Andreeff

  • Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy

    J A McCubrey;L S Steelman;S L Abrams;F E Bertrand

  • Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

    Negin Misaghian;Giovanni Ligresti;L. S. Steelman;Fred E. Bertrand

  • Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials

    Solko W. Schalm;Ola Weiland;Bettina E. Hansen;Michele Milella

Frequent Co-Authors

Francesco Cognetti
Francesco Cognetti Sapienza University of Rome
Aldo Scarpa
Aldo Scarpa University of Verona
Giampaolo Tortora
Giampaolo Tortora University of Verona
Diana Giannarelli
Diana Giannarelli Sapienza University of Rome
James A. McCubrey
James A. McCubrey East Carolina University
Roberto Salvia
Roberto Salvia University of Verona
Daniele Santini
Daniele Santini Università Campus Bio-Medico
Michele Reni
Michele Reni Vita-Salute San Raffaele University
Claudio Bassi
Claudio Bassi University of Verona
Maria Teresa Petrucci
Maria Teresa Petrucci Sapienza University of Rome

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Medicine, several online degrees and career pathways can complement or provide alternatives to traditional medical education in the USA. Online programs offer flexible options for advancing your healthcare career, whether your goal is to manage hospital systems, work in nursing, or specialize further.

A popular pathway is earning a Master of Health Administration from cahme-accredited programs, which focus on health systems leadership and management. Registered Nurses can pursue an rn to bsn online without clinicals to advance their qualifications with minimal time away from their current work.

For nurses seeking higher credentials, online doctorates are increasingly accessible. You can opt for the quickest dnp program to accelerate your career, or explore dnp programs without dissertation for a more practice-focused learning experience.

Online healthcare degrees allow for greater flexibility, empowering students to balance studies with work. Choosing the right program depends on your career goals, desired specialization, and preferred learning style.

Best Scientists Citing Michele Milella

Trending Scientists

Recently Published Articles